Obesity Featured Articles

  1. Overcome The 6 Most Common Hurdles To Turning Wearable Data Into Usable RWE 10/27/2026

    Wearable data is easy to collect but difficult to turn into trusted RWE. Explore six fixes for the most common data problems when using wearables in research.

  2. AI Saved Time. Employees Didn't Feel It. 10/27/2026

    An ankle injury kept me from attending the Veeva R&D & Quality Summit, but not from speaking with clinical research leaders about how AI is reshaping operations. I learned why saving time doesn’t always feel like progress — and why trust, change management, and human oversight matter as much as the technology itself.

  3. When To Build Out Your ClinOps Team — And Other Advice For First-Time Biotechs 10/26/2026

    Small biotechs shouldn't model their ClinOps headcount after Big Pharma. Instead, they need the right capabilities, oversight, and risk controls. Consultant Jessica Cordes explains.

  4. What Happens When Clinical Trial Patients Need Care Outside Of The Study? 10/26/2026

    Clinical trial patients may need care outside of the trial protocol. Discover how closing information gaps can protect safety, trial participation, and data integrity.

  5. Ossium's Unconventional Site Strategy For Studying A Novel Bone Marrow Donor Source 10/23/2026

    Ossium CEO Kevin Caldwell explains how an unconventional multisite Phase 1 trial is shaping the company's novel bone marrow product’s path ahead.

  6. Who Owns Your Clinical Trial Software When The Vendor Leaves? 10/22/2026

    When a clinical trial software vendor exits, sponsors still own the risk. Learn what to secure before signing a contract to protect data, validation, and continuity.

  7. What The New PDUFA Guidance Means For Drug Development 10/21/2026

    Learn how the FDA’s updated PDUFA meeting guidance affects sponsor engagement, preparation, and the way feedback shapes drug development.

  8. The Site Landscape Is Evolving, But How? Tufts CSDD Shares New Findings 10/20/2026

    Tufts CSDD data reveals how academic, independent, and network-affiliated clinical trial sites differ in growth, reach, staffing, and performance.

  9. Testing Early Treatment In Head And Neck Cancer Without Compromising Curative Care 10/20/2026

    Can early APG-157 treatment control head and neck cancer without delaying curative care? A Phase 3 trial puts timing, safety, and outcomes to the test.

  10. Founders, Fortitude, And Clinical Trials 10/20/2026

    After talking with six clinical trials-related company founders, I came away admiring the tenacity, fortitude, and curiosity it takes to turn an idea into a business — and keep it going through setbacks, uncertainty, and constant change.